OrbusNeich today announced that new clinical data presented at TCT 2013 show durable outcomes as well as excellent early healing and optimal neointimal suppression out to 24 months following placement of the COMBO Dual Therapy Stent. These results from the EGO-COMBO Study were presented by Stephen W.L. Lee, M.D., of the Queen Mary Hospital, University of Hong Kong, China, at the annual interventional cardiology conference in San Francisco.

Micell Technologies, Inc. today announced that imaging and clinical results from the DESSOLVE I and DESSOLVE II trials of its MiStent Sirolimus Eluting Absorbable Polymer Coronary Stent System (MiStent SES®) were presented at the 25th Annual Transcatheter Cardiovascular Therapeutics (TCT) Conference held in San Francisco, October 27 – November 1, 2013. The MiStent SES is a thin-strut drug-eluting stent distinguished by a rapidly absorbable coating designed to control drug release, and which was developed to optimize vessel healing in patients with coronary artery disease.

San Francisco has been good for CHAMPION PHOENIX. Earlier this year at the American College of Cardiology (ACC) scientific session, investigators reported that cangrelor reduced the rate of ischemic events, including stent thrombosis, during PCI, with no significant increase in severe bleeding. Using that data, they then identified clinical predictors of intraprocedural stent thrombosis Oct. 28 at the Transcatheter Cardiovascular Therapeutics (TCT) conference in San Francisco.

Interruption of dual antiplatelet therapy (DAPT) using newer-generation drug-eluting stents (DES) may not lead to a stent thrombosis, according to data presented Oct. 31 at the 2013 Transcatheter Cardiovascular Therapeutics (TCT) conference in San Francisco.

Women who underwent radial PCI had a lower rate of bleeding and vascular complications compared with women treated femorally, according to results of a late-breaking clinical trial presented Oct. 29 at the Transcatheter Cardiovascular Therapeutics Conference in San Francisco. But the overall procedural failure rate was three times higher in the radial group. 

The use of the STENTYS Self-Apposing® Stent, a paclitaxel-eluting stent (Taxol, Bristol-Myers Squibb), in certain patients with coronary bifurcation lesions has been safe and effective six months into a clinical trial, according to data presented Oct. 28 at the 2013 Transcatheter Cardiovascular Therapeutics (TCT) Conference in San Francisco. If longer-term follow-up confirms their findings, using this drug-eluting stent (DES) may also be less clinically complex than current DES.

Gregg W. Stone, MD, co-director of the Transcatheter Cardiovascular Therapeutics (TCT) conference in San Francisco, discussed the history of the 25-year-old event and its clinical trials with Cardiovascular Business in a two-part Q&A.

Marvin Woodall, former president of Johnson & Johnson Interventional Systems and a member of the board of directors at the Cardiovascular Research Foundation, has attended every Transcatheter Cardiovascular Therapeutics conference since its debut in 1988.